AnaptysBio Makes Deal With Celgene For Antibodies
This article was originally published in The Pink Sheet Daily
Executive Summary
AnaptysBio has gained another big partner in Celgene for its antibody discovery platform; bringing Celgene further into biologics.
You may also be interested in...
Anaptys Biosciences Inc.
According to the CEO of Anaptys Biosciences, therapeutic antibodies will continue to be the single largest growing segment in pharmaceuticals, but the number of companies providing solutions in this area is decreasing following a number of acquisitions. Anaptys will fill the gap with its somatic hypermutation technology platform for therapeutic antibody discovery and optimization. The platform replicates the natural process of mutagenesis occurring in B cells as part of the immune response, involving steps of immunoglobulin recombination, mutation, affinity maturation and selection.
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
Zafgen Drops Beloranib, But Its New Focus Raises Doubts
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.